Overexpression of decoy receptor 3 in synovial tissues of inflammatory arthritis

Clinical and Experimental Rheumatology

Volumn 30, Issue 2, 2012, Pages 171-177

  Chen, Ming Han ^a,b   Chen, Wei Sheng ^a,b   Tsai, Chang Youh ^b   Liao, Hsien Tzung ^c   Chen, Chun Hsiung ^d   Chou, Chung Tei ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Ankylosing spondylitis; DCR3; Osteoarthritis; Rheumatoid arthritis; Synovial tissue

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; DECOY RECEPTOR 3; EOSIN; HEMATOXYLIN;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL HYPERPLASIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LINING LAYER CELL; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MONOCYTE; MONONUCLEAR CELL; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SUBLINING LAYER CELL; SYNOVIOCYTE; SYNOVIUM; VASCULARIZATION;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; MACROPHAGES; MIDDLE AGED; MONOCYTES; OSTEOARTHRITIS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; SPONDYLITIS, ANKYLOSING; SYNOVIAL MEMBRANE; TAIWAN; UP-REGULATION;

EID: 84863750555     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. KHAN MA, VAN DER LINDEN SM Ankylosing spondylitis and other spondyloarthropathies. Rheum Dis Clin North Am 1990; 16: 551-79.
2. CHOU CT HLA-B27 and other related genes in ankylosing spondylitis in APLAR countries. APLAR J Rheumatol 2005; 8: 143-45.
3. GONZALEZ-ROCES S, ALVAREZ MV, GONZALEZ S et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 1997; 49: 116-23.
4. VAN DER HORST-BRUINSMA IE, LEMS WF, DIJKMANS BA A systematic comparison of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27: S43-9.
5. LORIES RJ, BAETEN DL Differences in pathophysiology between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27: S10-4.
6. CHOU CT, YANG JS, LEE MR Apoptosis in rheumatoid arthritis-expression of Fas, Fas-L, p53, and Bcl-2 in rheumatoid synovial tissues. J Pathol 2001; 193: 110-6.
7. FIRESTEIN GS, ECHEVERRI F, YEO M et al. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 1997; 94: 10895-900.
8. BAETEN D, KRUITHOF E, VAN DEN BOSCH F et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondyloarthropathy. Arthritis Rheum 2001; 44: 186-95.
9. BRAUN J, BOLLOW M, NEURE L et al. Use of immunohistologic and in-situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
10. VANDOOREN B, KRUITHOF E, YU DTY et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondyloarthropathy. Arthritis Rheum 2004; 50: 2942-53.
11. APPEL H, KUHNE M, SPIEKERMANN S et al. Immunohistochemical analysis of hip arthritis in ankylosing spomdylitis. Arthritis Rheum 2006; 54: 1805-13.
12. BENITO MJ, VEALE DJ, FITZGERALD O et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263-7.
13. FIRESTEIN GS, KATHERINE N, KARLFRIED R Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid synovium. Am J Pathol 1996; 149: 2143-51.
14. ASAHARA H, HASUNAMA T, KOBATA F et al. Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue. Clin Immunol Immunopathol 1996; 81: 27-34.
15. MATSUMOTO S, MULLER-LADNER ULF, GAY R et al. Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid synovial fibroblasts. J Rheumatol 1996; 23: 1345-52.
16. FIRESTEIN GS, YEO M, ZVAIFLER NJ Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995; 96: 1631-8.
17. SALMON M, SCHEEL-TOLLNER D, HUISSOON AP et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 1997; 99: 439-46.
18. WILEY SR, SCHOOLEY K, SMOLAK PJ et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-82.
19. THOMAS WD, HERSEY P TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1998; 161: 2195-200.
20. PITTI RM, MARSTERS SA, LAWRENCE DA et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699-703.
21. LIN WW, HSIEH SL Decoy receptor 3: A pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol 2011; 81: 838-47.
22. ZHANG J, SALCEDO TW, WAN X et al. Modulation of T-cell responses to alloantigens by TR6/ DcR3. J Clin Invest 2001; 107: 1459-68.
23. BAI C, CONNOLLY B, METZKER ML et al. Overexpresson of M68/ DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a fourgene cluster. Proc Natl Acad Sci 2000; 97: 1230-5.
24. OHSHIMA K, HARAOKA S, SUGIHARA M et al. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-1)-associated lymphomas. Cancer Lett 2000; 160: 89-97.
25. ZHANG J, SALCEDO TW, WAN X et al. Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest 2001; 107: 1459-68.
26. YU KY, KWON B, NI J et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHTmediated apoptosis. J Biol Chem 1999; 274: 13733-36.
27. WU YY, CHANG YC, HSU TL et al. Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3. J Biol Chem 2004; 279: 44211-8.
28. ROTH W, ISENMANN S, NAKAMURA M et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligandinduced apoptosis and chemotaxis. Cancer Res 2001; 61: 2759-65.
29. HAN B, WU J DcR3 protects islet beta cells from apoptosis through modulating Adcyap1 and Bank1 expression. J Immunol 2009; 183: 8157-66.
30. CHANG YC, HSU TL, LIN HH et al. Modulation of macrophage differentiation and activation by decoy receptor 3. J leukoc Biol 2004; 75: 486-96.
31. HSU TL, CHANG YC, CHEN SJ et al. Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol 2002; 168: 4846-53.
32. LEE CS, HU CY, TSAI HF et al. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin Exp Immunol 2008; 151: 383-90.
33. HAN B, MOORE PA, WU J et al. Overexpression of human decoy receptor3 in mice results in a systemic lupus erythematosus-like syndrome. Arthritis Rheum 2007; 56: 3748-58.
34. BAMIAS G, SIAKAVELLAS SI, STAMATELOPOULOS KS et al. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin Immunol 2008; 129: 249-55.
35. HAYASHI S, MIURA Y, NISHIYAMA T et al. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 2007; 56: 1067-75.
36. ARNETT FC, EDWORTHY SM, BLOCH DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
37. VAN DER LINDEN SM, VALKENBURG HA, CAST A Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
38. LAWRENCE JS, BREMNER JM, BIER F Osteoarthrosis. Prevalence in the population and relationship between symptoms and xray change. Ann Rheum Dis 1966; 25: 1-24.
39. TAK PP, VAN DER LUBBE PA, CAULI A et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995; 38: 1457-65.
40. IKEDA M, HOSODA Y, HIROSE S et al. Expression of vascular endothelial growth factor isoforms and their receptor Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 2000; 191: 426-33.
41. JACOBS TW, GOWN AM, YAZIJI H et al. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol 2000; 113: 251-8.
42. KRAAN MC, HARINGMAN JJ, POST WJ et al. Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis. Rheumatol 1999; 38: 1074-80.
43. BAETEN D, DEMETTER P, CUVELIER C et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000; 59: 945-53.
44. CHEN WS, CHEN CH, LIN KC et al. Immunohistological features of hip synovitis in ankylosing spondylitis with advanced hip involvement. Scand J Rheumatol 2009; 38: 154-5.
45. INMAN RD, EL-GABALAWY HS The immunology of ankylosing spondylitis and rheumatoid arthritis: a tale of similarities and dissimilarities. Clin Exp Rheumatol 2009; 27: S26-32.
46. APPEL H, LODDENKEMPER C, MIOSSEC P Rheumatoid arthritis and ankylosing spondylitis - pathology of acute inflammation. Clin Exp Rheumatol 2009; 27: S15-9.
47. SMITH JA, BARNES MD, HONG D et al. Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-gamma dysregulation. Arthritis Rheum 2008; 58: 1640-9.
48. VANDOOREN B, NOORDENBOS T, AMBARUS C et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum 2009; 60: 966-75.
49. BURGOS-VARGAS R, VAZQUEZ-MELLADO J The early clinical recognition of juvenileonset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum 1995; 38: 835-44.